NCT00158691View on ClinicalTrials.gov

Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas

PHASE3CompletedINTERVENTIONAL

Enrollment

296

Participants

Timeline

Start Date

March 31, 2001

Conditions

Head and Neck Cancer

Interventions

DRUG

Ethyol

Trial Locations (1)

44805

Centre Régional de Lutte contre le Cancer de Nantes-Atlantique, Nantes

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER

NCT00158691 - Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas | Biotech Hunter | Biotech Hunter